Trovagene receives European patent titled, ‘Methods for Detection of Nucleic Acid Sequences in Urine’

Trovagene, Inc. (Pink Sheets:   TROV), a developer of trans-renal molecular diagnostics, announced it has received notice of issuance of European Patent No. 2216416 entitled "Methods for Detection of Nucleic Acid Sequences in Urine."

This patent pertains to the detection of pathogenic infections from urine specimens and complements previously issued U.S. patents, including the reissued patent RE39920 for the detection of nucleic acids from viral, bacterial, fungal, mycoplasma, and protozoan infections in urine samples.  Other previously issued, related patents include EP0920539 for detection of fetal nucleic acids from maternal urine, and EP1634966 for detection of cancer-specific nucleic acids from a patient's urine sample.

"This patent is a valuable addition to our fundamental IP portfolio," said Dr. Antonius Schuh, chief executive officer of Trovagene.  "It provides a basis for diagnosing and monitoring viral, bacterial or parasitic infections using a sample that is stable, easy to collect, and truly non-invasive.  This provides a convenient method for sample collection anywhere in the world, whether in industrialized or developing countries."

SOURCE Trovagene, Inc.